Table 1.
Patient Characteristics
| Characteristic | Frequency (%) |
|---|---|
| Age, median y (range) | 62 (28–79) |
| Sex, women | 23 (56) |
| ECOG performance status | |
| 0 | 15 (36) |
| 1 | 20 (49) |
| 2 | 6 (15) |
| Time from diagnosis to going on study, median mo (range) | 10.9 (0.9–137.1) |
| Distant metastasesa | |
| Nodal | 6 (19) |
| Subcutaneous | 2 (6) |
| Bone | 5 (16) |
| Lung | 23 (72) |
| Liver | 4 (13) |
| Abdominal | 5 (16) |
| Brain | 2 (6) |
| Otherb | 3 (9) |
| Histological type | |
| MFH | 8 (20) |
| Sarcoma, NOS | 9 (22) |
| Fibrosarcoma, NOS | 3 (7) |
| Myxosarcoma | 1 (2) |
| Liposarcoma, NOS | 5 (12) |
| Leiomyosarcoma | 9 (22) |
| Endometrial stromal sarcoma | 1 (2) |
| Synovial sarcoma | 1 (2) |
| Hemangiosarcoma/angiosarcoma | 2 (5) |
| Hemangiopericytoma, NOS | 1 (2) |
| Neurofibrosarcoma | 1 (2) |
| Sarcoma site | |
| Pelvis | 3 (8) |
| Head (skull, face) | 2 (5) |
| Extremities | 16 (40) |
| Intra-abdominal, NOS | 5 (13) |
| Genitourinary, NOS | 1 (2) |
| Vascular, NOS | 2 (5) |
| Cardiac, muscle | 1 (3) |
| Fallopian tube | 1 (3) |
| Uterus | 5 (13) |
| Skin | 1 (3) |
| Pulmonary, lung | 1 (3) |
| Truncal, chest wall | 2 (5) |
| Differentiation (grade) | |
| High (grade 3 or 4) | 33 (80) |
| Low (grade 1 or 2) | 8 (20) |
| Status of primary tumor site | |
| Resected with no residual | 13 (32) |
| Resected with known residual | 7 (17) |
| Unresected | 8 (19) |
| Recurrent | 13 (32) |
| Prior adjuvant therapy, yes | 9 (22) |
ECOG indicates Eastern Cooperative Oncology Group; MFH, malignant fibrous histiocytoma; NOS, not otherwise specified.
a
Overall, 13 (32%) patients had multiple metastasis sites.
b
Other sites included right chest wall in rib cage, adrenal mass, and left lower thoracic paraspinal mass.